The Ontario Institute for Cancer Research is investing in a microfluidics technology developed at the University of Toronto in the hope that it will aid in the commercialization of new cancer therapies. The high-throughput digital microfluidics screening technology called a Smart Well Plate is a small device the size of a hand, has no moving parts, and may allow for less expensive screening of chemical libraries in the drug discovery process, says OICR's Chief Commercialization Officer Frank Stonebanks. Digital microfluidics simplifies the screening process, requiring a much smaller amount of cells and reagents to do the testing, OICR adds.
Money for Microfluidics
Apr 02, 2011